Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  34.50 28.05% 157.50 155.00 160.00 157.50 124.00 124.00 75,614 16:19:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.3 -2.1 -0.2 - 21

Feedback PLC Result of AGM & Proposed Share Consolidation

13/10/2022 2:55pm

UK Regulatory (RNS & others)


Feedback (LSE:FDBK)
Historical Stock Chart


From Aug 2022 to Feb 2023

Click Here for more Feedback Charts.

TIDMFDBK

RNS Number : 8407C

Feedback PLC

13 October 2022

Feedback plc

Result of AGM & Proposed Share Consolidation

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at the Annual General Meeting ("AGM") held today all resolutions were duly passed.

The results of the poll (including proxy votes on the resolutions) are included below.

 
 Resolutions              Votes For**    % of votes     Votes Against   % of votes      Votes          Total votes 
                                         cast***                        cast***         Withheld***    cast*** 
      1) To receive and 
       adopt the 
       Company's annual 
       accounts for the 
       year ended 31 
       May 2022 
       together 
       with the 
       Directors' 
       report and the 
       Auditors' report 
       thereon           1,435,070,825     100.00            0              0.00         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      2) To receive and 
       approve the 
       report on 
       Directors' 
       remuneration for 
       the year ended 
       31 May 
       2022               666,547,017       57.85       485,714,290        42.15         83,017,483     1,152,261,307 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      3) To re-appoint 
       Price Bailey LLP 
       as Auditor of 
       the Company       1,300,785,111     100.00            0              0.00         1,636,537      1,300,785,111 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      4) To authorise 
       the Directors to 
       determine the 
       fees payable to 
       the Auditor       1,435,070,825     100.00            0              0.00         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      5) To elect Anesh 
       Patel as a 
       Director of the 
       Company           1,435,037,825     100.00          33,000           0.00         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      6) To elect 
       Annemijn 
       Eschauzier as a 
       Director of the 
       Company           1,435,037,825     100.00          33,000           0.00         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      7) To re-elect 
       Rory Shaw as a 
       Director of the 
       Company            949,356,535      100.00            0              0.00        487,350,827      949,356,535 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
                                                   Special Business 
      8) That the 
       Directors be and 
       are hereby 
       generally and 
       unconditionally 
       authorised to 
       allot 
       relevant 
       securities 
       pursuant to 
       section 551 of 
       the Companies 
       Act 2006          1,388,179,455      96.73        46,891,370         3.27         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
            Special 
             Resolution 
             9) To 
             resolve 
             that the 
             Directors 
             be 
             empowered 
             to allot 
             equity 
             securities 
             for cash 
             and/or to 
             sell 
             equity 
             securities 
             held as 
             treasury 
             shares for 
             cash        1,388,596,455      96.76        46,474,370         3.24         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      10) That every 
       200 ordinary 
       shares of 
       GBP0.0025 each 
       in the capital 
       of the Company 
       are hereby 
       consolidated 
       into one 
       ordinary share 
       of GBP0.50        1,376,208,959      95.90        58,861,866         4.10         1,636,537      1,435,070,825 
                         -------------  -------------  --------------  --------------  --------------  --------------- 
      Special 
       resolution 
       11) That, the 
       Articles be 
       amended by the 
       insertion of a 
       new article 2.5   1,376,208,959      95.90        58,861,866         4.10         1,636,537       1,435,070,825 
 
 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** Percentages exclude "Votes Withheld".

*** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution.

**** "Total votes cast" do not include withheld votes.

Share Consolidation

Following the approval of the Consolidation Resolution (resolution 10 above), every 200 ordinary shares of GBP0.0025 each (the "Existing Shares") that are in issue as at 6.00 p.m. today will be consolidated into one new ordinary share of GBP0.50 each (the "New Ordinary Shares"). Other than the change in nominal value, the New Ordinary Shares arising on implementation of the Share Consolidation will have the same rights as the Existing Ordinary Shares, including voting and other rights.

The New Ordinary Shares arising from the Share Consolidation will be admitted to trading on AIM from 8.00 a.m. on 14 October 2022 ("Admission") with ISIN number GB00BJN59X09 and SEDOL code BJN59X0.

Total Voting Rights

Following Admission, the Company's issued share capital will comprise 13,334,659 New Ordinary Shares with voting rights. This figure of 13,334,659 New Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Conduct Authority.

Save as defined herein, capitalised terms have the same meaning as in the Company's notice of AGM which is available on the Company's website.

-Ends-

Enquiries:

 
 Feedback plc                             +44 (0) 20 3997 7634 
  Tom Oakley, CEO                          IR@fbk.com 
  Anesh Patel, CFO 
 
 Panmure Gordon (UK) Limited 
  (NOMAD and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)      +44 (0)20 7886 2500 
 
 Walbrook PR Ltd;                         Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome                   07980 541 893 or 07748 325 236 
                                           or 07884 664 686 
 

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKZMMGFFZGZZM

(END) Dow Jones Newswires

October 13, 2022 09:55 ET (13:55 GMT)

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230208 18:23:37